Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI

References

• Garga N, Lowenstein DH. Posttraumatic epilepsy: A major problem in desperate need of major advances. Epilepsy Currents 2006;6:1–5
   PubMedGoogle Scholar
• Gupta P, Ding K, Sayed N, Agostini M, Van Ness P, Madden C, Mickey B, D’Ambrosio R, Diaz-Arrastia RJ. Subtypes of post-traumatic epilepsy: clinical, electrophysiologic, and imaging features. Journal of Neurotrauma 2014;31:1439–1443
   Google Scholar
• Diamond ML, Ritter A, Failla MD, Boles JA, Conley YP, Kochanek PM, Wagner AK. IL-1β influences on post-traumatic epilepsy development: A genetics and biomarker cohort Study. Epilepsia 2014;55:1109–1119
   Google Scholar
• Darrah SD, Miller MA, Ren D, Hoh NZ, Scanlon JM, Conley YP, Wagner AK. Genetic variability in the glutamic acid decarboxylase gene: Associations with post-traumatic seizures after severe TBI. Epilepsy Research 2013;103:180–194
   PubMed Web of Science ®Google Scholar
• Wagner AK, Miller MA, Scanlon, J, Ren D, Kochanek PM, Conley YP. Adenosine A1 receptor gene variant associated with post-traumatic seizures after severe TBI. Epilepsy Research 2010;90:259–272
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Immonen R. Epilepsy related to traumatic brain injury. Neurotherapeutics 2014;11:286–296
   PubMed Web of Science ®Google Scholar
• Chang BS, Lowenstein DH. Quality Standards Subcommittee of the American Academy of N: Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury: Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2003;60:10–16
   PubMed Web of Science ®Google Scholar
• Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. New England Journal of Medicine 1990;323:497–502
   PubMed Web of Science ®Google Scholar
• Frey LC. Epidemiology of posttraumatic epilepsy: A critical review. Epilepsia 2003;44:11–17
   PubMed Web of Science ®Google Scholar
• Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioural effects of phenytoin prophylaxis of posttraumatic seizures. Journal of the American Medical Association 1991;265:1271–1277
   PubMed Web of Science ®Google Scholar
• Darrah SD, Chuang J, Mohler LM, Chen X, Cummings EE, Burnett T, Reyes-Littaua MC, Galang GN, Wagner AK. Dilantin therapy in an experimental model of traumatic brain injury: Effects of limited versus daily treatment on neurological and behavioural recovery. Journal of Neurotrauma 2011;28:43–55
   PubMed Web of Science ®Google Scholar
• Nakamura H, Osawa M, Yokoyama T, Yoshida K, Suzuki A. Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: Multicenter and open-label study (N01223), short term evaluation. Brain Nerve 2013;65:1083–1092
   PubMedGoogle Scholar
• Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, Stippler M, Fischer M, Sauber-Schatz EK, Fabio A, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurgical Focus 2008;25:E3
   PubMed Web of Science ®Google Scholar
• Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocritical Care 2010;12:165–172
   PubMed Web of Science ®Google Scholar
• Zou H, Brayer SW, Hurwitz M, Niyonkuru C, Fowler LE, Wagner AK. Neuroprotective, neuroplastic, and neurobehavioural effects of daily treatment with levetiracetam in experimental traumatic brain injury. Neurorehabilitation Neural Repair 2013;27:878–888
   PubMed Web of Science ®Google Scholar
• Klein P, Herr D, Pearl PL, Natale J, Levine Z, Nogay C, Sandoval F, Trzcinski S, Atabaki SM, Tsuchida T, et al. Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. Archives of Neurology 2012;69:1290–1295
   PubMed Web of Science ®Google Scholar
• Hwabejire JO, Imam AM, Jin G, Liu B, Li Y, Sillesen M, Jepsen CH, Lu J, deMoya MA, Alam HB. Differential effects of fresh frozen plasma and normal saline on secondary brain damage in a large animal model of polytrauma, hemorrhage and traumatic brain injury. Journal of Trauma and Acute Care Surgery 2013;75:968–974; discussion 974–975
   PubMed Web of Science ®Google Scholar
• Cuomo O, Rispoli V, Leo A, Politi GB, Vinciguerra A, di Renzo G, Cataldi M. The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion. PLOS ONE 2013;8:e80852
   PubMed Web of Science ®Google Scholar
• Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001;10:287–293
   PubMed Web of Science ®Google Scholar
• Folkersma H, Foster Dingley JC, van Berckel BN, Rozemuller A, Boellaard R, Huisman MC, Lammertsma AA, Vandertop WP, Molthoff CF. Increased cerebral(R)-[(11)C]PK11195 uptake and glutamate release in a rat model of traumatic brain injury: A longitudinal pilot study. Journal of Neuroinflammation 2011;8:67
   PubMed Web of Science ®Google Scholar
• Thomale UW, Griebenow M, Mautes A, Beyer TF, Dohse NK, Stroop R, Sakowitz OW, Unterberg AW, Stover JF. Heterogeneous regional and temporal energetic impairment following controlled cortical impactinjury in rats. Neurological Research 2007;29:594–603
   PubMed Web of Science ®Google Scholar
• Hovda DA, Lee SM, Smith ML, Von Stuck S, Bergsneider M, Kelly D, Shalmon E, Martin N, Caron M, Mazziotta J, et al. The neurochemical and metabolic cascade following brain injury: Moving from animal models to man. Journal of Neurotrauma 1995;12:903–906
   PubMed Web of Science ®Google Scholar
• Wagner AK, Fabio A, Puccio AM, Hirschberg R, Li W, Zafonte RD, Marion DW. Gender associations with cerebrospinal fluid glutamate and lactate/pyruvate levels after severe traumatic brain injury. Critical Care Medicine 2005;33:407–413
   PubMed Web of Science ®Google Scholar
• De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: The profile of a novel anticonvulsant drug-part I: Preclinical data. CNS Drug Review 2007;13:43–56
   PubMedGoogle Scholar
• Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: Extracellular pharmacokinetics and effect on taurine in rat brain. British Journal of Pharmacology 2001;133:867–874
   PubMed Web of Science ®Google Scholar
• De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Review 2007;13:57–78
   PubMedGoogle Scholar
• Zweckberger K, Hackenberg K, Jung CS, Hertle DN, Kiening KL, Unterberg AW, Sakowitz OW. Cerebral metabolism after early decompression craniotomy following controlled cortical impact injury in rats. Neurological Research 2011;33:875–880
   PubMed Web of Science ®Google Scholar
• Kruer RM, Harris LH, Goodwin H, Kornbluth J, Thomas KP, Slater LA, Haut ER. Changing trends in the use of seizure prophylaxis after traumatic brain injury: A shift from phenytoin to levetiracetam. Journal of Critical Care 2013;28:883.e9–e13
   PubMed Web of Science ®Google Scholar
• Bales J, Wagner AK, Kline AE, Dixon CE. Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. Neuroscience and Biobehavioral Reviews 2009;33:981–1003
   PubMed Web of Science ®Google Scholar
• Wagner AK, Hurwitz M, Brayer S, Zou H, Failla MD, Arenth PM, Skidmore E, Garman R, Thiels E. Non-spatial pre-training in the water maze as a clinically relevant model for evaluating learning and memory in experimental TBI. Neurobiology of Learning and Memory 2013;106:71–86
   PubMed Web of Science ®Google Scholar
• Tanaka S, Tanaka T. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy. Epileptic Disorders 2013;15:132–141
   PubMed Web of Science ®Google Scholar
• Fonkem E, Bricker P, Mungall D, Aceves J, Ebwe E, Tang W, Kirmani B. The role of levetiracetam in treatment of seizures in brain tumor patients. Frontiers in Neurology 2013;4:153
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Maren Staack A, Wisniewski I. Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre. Epileptic Disorders 2012;14:379–387
   PubMed Web of Science ®Google Scholar
• Pachet A, Friesen S, Winkelaar D, Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Injury 2003;17:715–722
   PubMed Web of Science ®Google Scholar
• Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Injury 2004;18:1–31
   PubMed Web of Science ®Google Scholar
• Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocritical Care 2006;5:71–78
   PubMed Web of Science ®Google Scholar
• Smith GR, Brenneman DE, Zhang Y, Du Y, Reitz AB. Small-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties. Journal of Molecular Neuroscience 2014;52:446–458
   Google Scholar
• Tello I, Campos-Pena V, Montiel E, Rodriguez V, Aguirre-Moreno A, Leon-Rivera I, Del Rio-Portilla F, Herrera-Ruiz M, Villeda-Hernandez J. Anticonvulsant and neuroprotective effects of oligosaccharides from lingzhi or reishi medicinal mushroom, Ganoderma lucidum (higher basidiomycetes). International Journal of Medicinal Mushrooms 2013;15:555–568
   PubMed Web of Science ®Google Scholar
• Nowack A, Malarkey EB, Yao J, Bleckert A, Hill J, Bajjalieh SM. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS One 2011;6:e29560
   PubMed Web of Science ®Google Scholar
• Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: Clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Development 2011;33:289–293
   PubMed Web of Science ®Google Scholar
• Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. The Journal of Pharmaceutical and Experimental Therapy 1998;284:474–479
   PubMed Web of Science ®Google Scholar
• Benge JF, Phenis RA, Bernett A, Cruz-Laureano D, Kirmani BF. Neurobehavioural effects of levetiracetam in patients with traumatic brain injury. Frontiers in Neurology 2013;4:195
   PubMed Web of Science ®Google Scholar
• Ravizza T, Noe F, Zardoni D, Vaghi V, Sifringer M, Vezzani A. Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiology of Disease 2008;31:327–333
   PubMed Web of Science ®Google Scholar
• Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, De Simoni MG. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures. Journal of Neuroscience 1999;19:5054–5065
   PubMed Web of Science ®Google Scholar
• Kumar R, Boles JA, Failla MD, Wagner AK. Chronic inflammation characterization after severe traumatic brain injury: Characterization and associations with outcome 6 and 12 months postinjury. Journal of Head Trauma Rehabilitation 2014. PMID: 24901329 [Epub ahead of print]
   Google Scholar